Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients

A Phase II Randomized, Double-blind Placebo-controlled Trial of Fecal Microbiota Transplantation for Vancomycin-resistant Enterococcus and Carbapenem-resistant Enterobacteriaceae

Vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Enterobacteriaceae (CRE) are multi-drug resistant organisms (MDROs) associated with healthcare settings and are a high priority for containment in public health. Healthcare-associated infections (HAIs) like VRE and CRE lengthen the duration of a hospital stay, increase the cost of hospitalization, and increase mortality. Because colonization precedes infection, prevention or treatment of VRE/CRE colonization is essential. We propose a treatment approach to promote gut decolonization by VRE and CRE without using antibiotics. Participants enrolled in this study will be randomized a one-time dose of either study drug or placebo, will be followed for 6 months, and will submit stool samples for analysis of several outcomes for the trial.

Study Overview

• Status: Withdrawn
• Conditions: Clostridium Difficile Infection
• Intervention / Treatment: Drug: FMT Capsule DE; Drug: Placebo oral capsule

Detailed Description

This is a phase II, double-blind, randomized, placebo controlled trial assessing the effects of one-time oral FMT on the composition and function of the gut microbiome compared to placebo in a population of patients with baseline CRE or VRE gut colonization. Participants will be adults who have had two consecutive positive stool cultures for VRE or CRE and meet all inclusion/exclusion criteria. Patients (N=90) will be randomized at a 1:1 ratio. Randomization will be double-blinded. Each subject will be followed for 6 months. Stool samples will be taken at baseline and from subjects weekly for 4 weeks, then every 4 weeks for 8 weeks, then at 6 months regardless of treatment group. All patients will be asked to complete a stool diary

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Cognitively intact and willing to provide informed consent
• Willing and able to comply with all study procedures for the duration of the study
• Age 18 years or older
• Two positive stool cultures for CRE or VRE (positive for the same organism on both cultures). The most recent stool culture must be within 14 days of randomization.
• Women of childbearing potential in a sexual relationship with men must use an acceptable method of contraception (including, but not limited to, barrier with additional spermicidal foam or jelly, intrauterine device, hormonal contraception started at least 30 days before enrollment into the study, or intercourse with men who underwent a vasectomy) for 4 weeks following completion of the study treatment.
• Males must agree to avoid impregnation of women during and for 4 weeks following completion of the study treatment through the use of an acceptable method of contraception (including but not limited to, barrier with additional spermicidal foam or jelly or vasectomy).
• Able to take the test capsule successfully with no signs or symptoms of dysphagia.

Exclusion Criteria:

• Admitted to an intensive care unit (ICU) for medical reasons (not just boarding).

Patients residing in a nursing home, long-term care facility or rehabilitation center may be enrolled.

• Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to randomization. Does not include antibiotics used for prophylaxis or topical antibiotics.
• Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4 weeks.
• Unwilling to withhold probiotics for a minimum of 48 hours prior to providing a screening stool sample.
• Previous FMT or microbiome-based products in the last 90 days.
• Active antibiotic-resistant bacteria (ARB) or gastrointestinal infection at time of enrollment.
• Any other gastrointestinal illness including diarrhea.
• Known or suspected toxic megacolon and or known small bowel ileus.
• Bowel obstruction or other gut motility issues as noted by the patient or in the electronic medical record.
• Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment not including appendectomy or cholecystectomy.
• History of total colectomy or bariatric surgery.
• Concurrent intensive induction chemotherapy, radiation therapy, or biologic treatment for an active malignancy. Patients on maintenance chemotherapy may be enrolled after consultation with the medical monitor.
• Patients with severe anaphylactic or anaphylactoid food allergy.
• Solid organ transplant recipients ≤90 days post-transplant or on active treatment for rejection.
• Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-tumor necrosis factor (anti-TNF) will be permitted. Participants taking glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after consultation with the medical monitor.
• If At risk of CMV/EBV associated disease (at discretion of investigators, e.g. immunocompromised participant), negative Immunoglobulin G (IgG) testing for cytomegalovirus (CMV) or Epstein Barr Virus (EBV).
• Cognitive impairment at the time of enrollment.
• Expected life expectancy <6 months.
• Inability (e.g. dysphagia) to or unwilling to swallow capsules.
• Unable or unwilling to comply with protocol requirements.
• Any condition that would jeopardize the safety or rights of the patient, would make it unlikely for the patient to complete the study, or would confound the results of the study.
• Females who are pregnant, lactating, or planning to become pregnant during the study.

Female patients of childbearing potential will take a pregnancy test and be excluded if pregnant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FMT Capsule DE	Drug: FMT Capsule DE; 30 capsule one-time oral dose
Placebo Comparator: Placebo Oral Capsule; Placebo Capsule	Drug: Placebo oral capsule; 30 capsule one-time oral dose; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare incidence of VRE/CRE decolonization between FMT Capsule double encapsuled (DE) and placebo	VRE/CRE decolonization is defined by absence of VRE/CRE on stool culture using standard laboratory techniques.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VRE/CRE infection at Day 3, Day 10, and Week 4 following randomization.	VRE/CRE infection will be defined as an associated bacteremia, urinary tract infection, or would-related infection.	1 month
Microbial engraftment assessed by microbial disruption index (MDI) at Day 3, Day 10, and Week 4 following randomization	VRE/CRE type and strain level engraftment, using whole genome sequencing laboratory techniques	1 month
Antibiotic resistant bacteria (ARB) decolonization at Day 10 after randomization.	ARB testing will be done with Acuitas (OpGen) MDRO test or a similar platform	10 days
Antibiotic resistant bacteria (ARB) infection at Day 3, Day 10, Week 4 after randomization, and time to infection if ARB infection occurs	ARB infection will be defined as extended spectrum beta lactamase clinical infection.	1 month
Adverse events/serious adverse events through Day 10, Week 4, and Month 6 following randomization.	Safety of FMT Capsule DE compared to placebo. Incidence of newly acquired transmissible infectious diseases that are considered adverse events of special interest (AESI).	6 months

Collaborators and Investigators

• Sponsor: University of Wisconsin, Madison
• Investigators: Principal Investigator: Nasia Safdar, MD PhD, Infectious Disease, School of Medicine & Public Health, University of Wisconsin-Madison

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2022
• Primary Completion (Anticipated): September 1, 2022
• Study Completion (Anticipated): June 30, 2025

Study Registration Dates

• First Submitted: August 21, 2018
• First Submitted That Met QC Criteria: August 22, 2018
• First Posted (Actual): August 23, 2018

Study Record Updates

• Last Update Posted (Actual): February 23, 2021
• Last Update Submitted That Met QC Criteria: February 19, 2021
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Clostridium Infections
• Other Study ID Numbers: W81XWH18PRMPCTA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No